1. Home
  2. LILAK vs ARDX Comparison

LILAK vs ARDX Comparison

Compare LILAK & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Latin America Ltd. Class C

LILAK

Liberty Latin America Ltd. Class C

HOLD

Current Price

$7.71

Market Cap

1.7B

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$7.78

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LILAK
ARDX
Founded
2017
2007
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
LILAK
ARDX
Price
$7.71
$7.78
Analyst Decision
Hold
Strong Buy
Analyst Count
1
10
Target Price
$8.20
$12.95
AVG Volume (30 Days)
944.0K
6.6M
Earning Date
02-18-2026
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,433,000,000.00
$398,234,000.00
Revenue This Year
$1.37
$22.65
Revenue Next Year
N/A
$31.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
58.12
52 Week Low
$4.23
$3.21
52 Week High
$9.13
$8.40

Technical Indicators

Market Signals
Indicator
LILAK
ARDX
Relative Strength Index (RSI) 51.50 64.74
Support Level $7.34 $6.73
Resistance Level $8.11 $7.25
Average True Range (ATR) 0.28 0.57
MACD 0.10 0.13
Stochastic Oscillator 69.81 80.31

Price Performance

Historical Comparison
LILAK
ARDX

About LILAK Liberty Latin America Ltd. Class C

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: